Momenta Pharmaceuticals, Inc.
 (MNTA)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Jun. 18, 2015, 5:36 PM
    | Jun. 18, 2015, 5:36 PM | 4 Comments
  • May 15, 2014, 3:51 PM
    • Shares of Momenta Pharmaceuticals (MNTA +11.3%) are up on slightly higher volume in response to a federal judge's tossing of Teva's (TEVA -0.9%) lawsuit accusing the FDA of acting improperly by not demanding additional testing of generic forms of Copaxone before clearing them for marketing.
    • Teva gets a "A" for effort in trying to stop competitors from selling their generic offerings especially since it is usually on the other side of the aisle. The U.S. Supreme Court has yet to rule on its patent infringement case vs Mylan and Sandoz.
    | May 15, 2014, 3:51 PM
  • May 15, 2014, 12:46 PM
    | May 15, 2014, 12:46 PM
  • Apr. 21, 2014, 9:13 AM
    | Apr. 21, 2014, 9:13 AM
  • Mar. 31, 2014, 12:47 PM
    | Mar. 31, 2014, 12:47 PM | 4 Comments
  • Mar. 31, 2014, 11:05 AM
    | Mar. 31, 2014, 11:05 AM | 1 Comment
  • Jul. 26, 2013, 4:37 PM

    Momenta Pharmaceuticals (MNTA) jumped 11.73% Friday after the U.S. Court of Appeals for the Federal Circuit invalidated "several" Copaxone (TEVA) patents, "potentially clear[ing] the way for market entry of a generic [version] as early as May 2014." Bernstein's Ronny Gal says MNTA could hit $30/ share if the company "is able to introduce the first generic Copaxone" by that date.

    | Jul. 26, 2013, 4:37 PM | 3 Comments
  • Jun. 25, 2013, 9:12 AM

    Momenta Pharmaceuticals (MNTA) says the U.S. Patent Office has issued "the first U.S. patent from a patent family related to sialylated Fc-containing products." The patent was issued to The Rockefeller University and the company is the exclusive licensee. Shares +2.6% premarket. (PR)

    | Jun. 25, 2013, 9:12 AM
  • Apr. 30, 2013, 3:43 PM

    Momenta Pharmaceuticals (MNTA -3.7%) slides after reporting a wider than expected Q1 loss this morning. The company attributes the miss to the January 2012 launch of a competitor's generic Lovenox, causing decreased unit sales and lower market share, which in turn led to lower prices in response to competitor pricing reductions.

    | Apr. 30, 2013, 3:43 PM
  • Nov. 19, 2012, 5:38 PM
    After-hours top gainers, as of 5:15 p.m.: KKD +10.8%. LTRE +7.1%. GLUU +4.3%. QIHU +4.2%. RYL +3.4%.
    After-hours top losers: MNTA -7.7%. MMLP -4.7%. JACK -4.7%. OVTI -4.1%. DELL -3.6%.
    | Nov. 19, 2012, 5:38 PM
  • Aug. 15, 2012, 1:48 PM
    Questcor (QCOR +2%) trades up today after being mentioned positively at BofA/Merrill. The firm says that after taking a meeting with Momenta (MNTA), it's convinced a generic version of QCOR's Acthar is unlikely near-term. Concerns over competition for Acthar have been a deep overhang on the stock.
    | Aug. 15, 2012, 1:48 PM
  • Jul. 20, 2012, 12:25 PM

    Momenta Pharmaceutical (MNTA -5.7%) takes a hit after UBS downgraded the shares to Neutral earlier this morning, citing limited near-term catalysts and cash burn following the recent negative court ruling in the Copaxone case. The firm retains its price target of $15.

    | Jul. 20, 2012, 12:25 PM
  • Jun. 25, 2012, 1:00 PM

    Momenta Pharmaceuticals (MNTA -19%) gets slammed today after this weekend's unfavorable ruling against the company in the Copaxone patent litigation brought against the company by Teva (TEVA +5.6%). Oppenheimer says the stock still has compelling long-term value , despite pressure over the near-term.

    | Jun. 25, 2012, 1:00 PM
  • Jun. 25, 2012, 9:06 AM
    Premarket gainers: LXRX +8%. TEVA +7%. QSFT +6%.
    Losers: VTUS -53%. MNTA -23%. SHPGY -12%. CEL -7%. ALU -6%. ARNA -6%. NOK -5%. ING -5%.
    | Jun. 25, 2012, 9:06 AM
  • Jun. 24, 2012, 9:07 AM

    Teva Pharmaceutical (TEVA) is +10.5% in Tel Aviv following the favorable ruling on its Copaxone patent in a case against Momenta (MNTA) and Mylan (MYL). While industry watchers had assumed Teva would prevail, with ~35% of its EPS at risk, a hearty sigh of relief isn't surprising.

    | Jun. 24, 2012, 9:07 AM | 11 Comments
  • Feb. 9, 2012, 2:49 PM
    Momenta Pharmaceuticals (MNTA -2.6%) is trading down after reporting a Q4 net loss, reversing year-ago gains and missing forecasts. Revenue plummeted 49% Y/Y on lower sales of enoxaparin, a key customer's drug used to treat blocked arteries.
    | Feb. 9, 2012, 2:49 PM
Company Description
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.
Sector: Healthcare
Industry: Biotechnology
Country: United States